Purple Biotech Ltd PPBT.TA Stock
Purple Biotech Ltd Price Chart
Purple Biotech Ltd PPBT.TA Financial and Trading Overview
Purple Biotech Ltd stock price | 23.5 ILA |
Previous Close | 59.8 ILA |
Open | 59.8 ILA |
Bid | 62 ILA x N/A |
Ask | 62.9 ILA x N/A |
Day's Range | 59.8 - 60.3 ILA |
52 Week Range | 50.1 - 96.7 ILA |
Volume | 16.41K ILA |
Avg. Volume | 30.9K ILA |
Market Cap | 126.66M ILA |
Beta (5Y Monthly) | 1.328767 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.34 ILA |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | October 30, 2012 |
1y Target Est | N/A |
PPBT.TA Valuation Measures
Enterprise Value | 96.15M ILA |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 255.50847 |
Enterprise Value/Revenue | N/A |
Enterprise Value/EBITDA | -4.756 |
Trading Information
Purple Biotech Ltd Stock Price History
Beta (5Y Monthly) | 1.328767 |
52-Week Change | -26.90% |
S&P500 52-Week Change | 20.43% |
52 Week High | 96.7 ILA |
52 Week Low | 50.1 ILA |
50-Day Moving Average | 67.88 ILA |
200-Day Moving Average | 67.36 ILA |
PPBT.TA Share Statistics
Avg. Volume (3 month) | 30.9K ILA |
Avg. Daily Volume (10-Days) | 29.32K ILA |
Shares Outstanding | 210.05M |
Float | 195.88M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 0% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -21.21% |
Return on Equity (ttm) | -36.72% |
Income Statement
Revenue (ttm) | N/A |
Revenue Per Share (ttm) | N/A |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -120000 ILA |
EBITDA | -20215000 ILA |
Net Income Avi to Common (ttm) | -19249000 ILA |
Diluted EPS (ttm) | -0.4 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 23.12M ILA |
Total Cash Per Share (mrq) | 0.12 ILA |
Total Debt (mrq) | 467K ILA |
Total Debt/Equity (mrq) | 0.99 ILA |
Current Ratio (mrq) | 4.346 |
Book Value Per Share (mrq) | 0.236 |
Cash Flow Statement
Operating Cash Flow (ttm) | -17599000 ILA |
Levered Free Cash Flow (ttm) | -10137125 ILA |
Profile of Purple Biotech Ltd
Country | Israel |
State | N/A |
City | Rehovot |
Address | 4 Oppenheimer Street |
ZIP | 7670104 |
Phone | 972 3 933 3121 |
Website | https://purple-biotech.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 20 |
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company for the Phase 2 clinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy; and Mor Research Applications. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Q&A For Purple Biotech Ltd Stock
What is a current PPBT.TA stock price?
Purple Biotech Ltd PPBT.TA stock price today per share is 23.5 ILA.
How to purchase Purple Biotech Ltd stock?
You can buy PPBT.TA shares on the Tel Aviv exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Purple Biotech Ltd?
The stock symbol or ticker of Purple Biotech Ltd is PPBT.TA.
Which industry does the Purple Biotech Ltd company belong to?
The Purple Biotech Ltd industry is Biotechnology.
How many shares does Purple Biotech Ltd have in circulation?
The max supply of Purple Biotech Ltd shares is 2.7M.
What is Purple Biotech Ltd Price to Earnings Ratio (PE Ratio)?
Purple Biotech Ltd PE Ratio is now.
What was Purple Biotech Ltd earnings per share over the trailing 12 months (TTM)?
Purple Biotech Ltd EPS is -0.34 ILA over the trailing 12 months.
Which sector does the Purple Biotech Ltd company belong to?
The Purple Biotech Ltd sector is Healthcare.